$GPFT
Grapefruit USA, Inc Stock $gpft

$gpft Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023697 Filed on August 22, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2021 Q4
Revenue	$2.962K	$24.06K	$2.180K
YoY Change	-98.07%	-70.83%	-99.8%
Cost Of Revenue	$62.76K	$162.5K	$192.5K
YoY Change	-81.87%	3.36%	-80.87%
Gross Profit	-$59.80K	-$138.4K	-$190.3K
YoY Change	-68.95%	85.32%	-321.6%
Gross Profit Margin	-2018.77%	-575.13%	-8727.98%
Selling, General & Admin	$342.8K	$728.0K	$537.6K
YoY Change	-17.41%	37.98%	32.7%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$14.62K	$20.67K	$23.62K
YoY Change	-37.76%	-11.97%	-154.7%
% of Gross Profit
Operating Expenses	$342.8K	$728.0K	$537.6K
YoY Change	-17.41%	37.98%	32.7%
Operating Profit	-$402.6K	-$866.4K	-$727.9K
YoY Change	-33.75%	43.85%	127.97%
Interest Expense	-$355.6K	-$471.3K	-$526.0K
YoY Change	-5.03%	50.89%	-98.42%
% of Operating Profit
Other Income/Expense, Net	-$355.6K	-$498.9K
YoY Change	-5.03%	-32.98%
Pretax Income	-$758.2K	-$1.365M	-$1.760M
YoY Change	-22.8%	1.38%	-129.26%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$758.2K	-$1.365M	-$1.760M
YoY Change	-22.78%	1.38%	-129.26%
Net Earnings / Revenue	-25597.81%	-5673.84%	-80711.01%
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	-$1.322K	-$2.440K	-$3.414K
COMMON SHARES
Basic Shares Outstanding	600.3M shares	559.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q3	2022 Q2	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.58K	$5.040K	$9.100K
YoY Change	-36.82%	-97.32%	-96.97%
Cash & Equivalents	$23.58K	$5.035K	$9.095K
Short-Term Investments
Other Short-Term Assets	$3.643K	$1.143K
YoY Change	-96.81%	-99.15%
Inventory	$337.5K	$339.3K	$389.3K
Prepaid Expenses
Receivables	$22.98K	$22.38K	$278.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$644.5K	$404.7K	$767.3K
YoY Change	-23.99%	-62.89%	-19.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.711M	$1.725M	$1.770M
YoY Change	-7.36%	-8.57%	-7.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$7.460K	$7.459K	$7.459K
YoY Change	0.0%	-0.01%	-0.01%
Total Long-Term Assets	$2.071M	$1.986M	$2.049M
YoY Change	-5.41%	-3.8%	-2.44%
TOTAL ASSETS
Total Short-Term Assets	$644.5K	$404.7K	$767.3K
Total Long-Term Assets	$2.071M	$1.986M	$2.049M
Total Assets	$2.715M	$2.391M	$2.816M
YoY Change	-10.6%	-24.22%	-7.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.164M	$1.111M	$1.035M
YoY Change	42.29%	49.57%
Accrued Expenses	$1.238M	$972.5K	$1.110M
YoY Change	25.57%	7.87%	32.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.081M	$3.008M	$3.935M
YoY Change	39.6%	34.92%	241.4%
Total Short-Term Liabilities	$7.913M	$7.281M	$7.704M
YoY Change	65.34%	63.36%	75.9%
LONG-TERM LIABILITIES
Long-Term Debt	$911.3K	$910.4K	$916.3K
YoY Change	-63.08%	-59.28%	-71.95%
Other Long-Term Liabilities	$19.16K	$3.350K	$11.10K
YoY Change		-81.94%	-86.46%
Total Long-Term Liabilities	$930.5K	$913.8K	$927.4K
YoY Change	-62.3%	-59.47%	-72.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.913M	$7.281M	$7.704M
Total Long-Term Liabilities	$930.5K	$913.8K	$927.4K
Total Liabilities	$8.844M	$8.195M	$8.631M
YoY Change	22.03%	22.1%	11.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.43M	-$18.68M	-$16.83M
YoY Change
Common Stock	$60.68K	$58.53K	$55.72K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.122M	-$5.797M	-$5.808M
YoY Change
Total Liabilities & Shareholders Equity	$2.715M	$2.391M	$2.816M
YoY Change	-10.6%	-24.22%	-7.64%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2021 Q4
OPERATING ACTIVITIES
Net Income	-$758.2K	-$1.365M	-$1.760M
YoY Change	-22.78%	1.38%	-129.26%
Depreciation, Depletion And Amortization	$14.62K	$20.67K	$23.62K
YoY Change	-37.76%	-11.97%	-154.7%
Cash From Operating Activities	-$36.16K	-$24.02K	-$204.8K
YoY Change	-81.11%	-95.6%	-71.38%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	54.71K	23.91K	176.6K
YoY Change	18.55%	-92.52%	-79.35%
NET CHANGE
Cash From Operating Activities	-36.16K	-24.02K	-204.8K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	54.71K	23.91K	176.6K
Net Change In Cash	18.55K	-110.0	-28.22K
YoY Change	-112.3%	-99.96%	-121.05%
FREE CASH FLOW
Cash From Operating Activities	-$36.16K	-$24.02K	-$204.8K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	-$36.16K	-$24.02K	-$204.8K
YoY Change	-80.54%	-95.38%	-71.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	GPFT	Selling Expenses SellingExpenses		usd
	GPFT	Selling Expenses SellingExpenses		usd
	GPFT	Gain Loss On Extinguishment Of Debt Related Parties GainLossOnExtinguishmentOfDebtRelatedParties		usd
	dei	Entity Registrant Name EntityRegistrantName	GRAPEFRUIT USA, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	GPFT	Gain Loss On Extinguishment Of Debt Related Parties GainLossOnExtinguishmentOfDebtRelatedParties		usd
	GPFT	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt		usd
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-50099
	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	GPFT	Loss On Legal Settlement LossOnLegalSettlement		usd
	GPFT	Gain Loss On Inventory Valuation GainLossOnInventoryValuation		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001205181
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	GPFT	Increase Decrease In Accrued Executive Compensation IncreaseDecreaseInAccruedExecutiveCompensation		usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	GPFT	Shares Issued For Debt Settlement With Related Parties SharesIssuedForDebtSettlementWithRelatedParties		usd
	GPFT	Shares Issued For Compensation SharesIssuedForCompensation		usd
	GPFT	Stock Open Compensation StockOpenCompensation		usd
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q2	GPFT	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo		usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive		usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues		usd
	GPFT	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Reclassification To Equity FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationToEquity		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4451059
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1000 Northwest Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Mid-Town Brandy Wine
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 1200-3094
	dei	Entity Address City Or Town EntityAddressCityOrTown	Wilmington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	DE
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19801
	dei	City Area Code CityAreaCode	310
	dei	Local Phone Number LocalPhoneNumber	575-1175
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	GPFT
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	600293195	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5035	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9095	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22379	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	278422	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	339312	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	389282	usd
CY2022Q2	GPFT	Licensee Agreement LicenseeAgreement	24200	usd
CY2021Q4	GPFT	Licensee Agreement LicenseeAgreement	37400	usd
CY2022Q2	GPFT	Operating Lease Right Of Use Asset Current OperatingLeaseRightOfUseAssetCurrent	12582	usd
CY2021Q4	GPFT	Operating Lease Right Of Use Asset Current OperatingLeaseRightOfUseAssetCurrent	53123	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1143	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	404651	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	767322	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1725261	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1769627	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3346	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21763	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	250000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	250000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7459	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7459	usd
CY2022Q2	us-gaap	Assets Assets	2390717	usd
CY2021Q4	us-gaap	Assets Assets	2816171	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	313050	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	262839	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	876887	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1014653	usd
CY2022Q2	GPFT	Interest Payable Related Parties InterestPayableRelatedParties	83067	usd
CY2021Q4	GPFT	Interest Payable Related Parties InterestPayableRelatedParties	29959	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1265826	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	702581	usd
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	530388	usd
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	541697	usd
CY2022Q2	GPFT	Subscription Payable Current SubscriptionPayableCurrent	389823	usd
CY2021Q4	GPFT	Subscription Payable Current SubscriptionPayableCurrent	251727	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3498	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	127392	usd
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	18964	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	31166	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12582	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65486	usd
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	90043	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	325089	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2676005	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	3640959	usd
CY2022Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1111398	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1035114	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7281488	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7703573	usd
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	7669	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3346	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11097	usd
CY2022Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	910411	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	908617	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	913757	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	927383	usd
CY2022Q2	us-gaap	Liabilities Liabilities	8195245	usd
CY2021Q4	us-gaap	Liabilities Liabilities	8630956	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	585293195	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	585293195	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	557162744	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	557162744	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	58529	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	55716	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12819736	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	10962797	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18675659	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16826164	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-5797394	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-5807651	usd
CY2022Q2	us-gaap	Minority Interest MinorityInterest	-7134	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-7134	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5804528	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5814785	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2390717	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2816171	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24062	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	82489	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29711	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	433304	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	162450	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	157163	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	234311	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	580598	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	-138388	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	-74674	usd
	us-gaap	Gross Profit GrossProfit	-204600	usd
	us-gaap	Gross Profit GrossProfit	-147294	usd
CY2021Q2	GPFT	Selling Expenses SellingExpenses	-1636	usd
	GPFT	Selling Expenses SellingExpenses	1960	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	727976	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	529246	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	967515	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	930658	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	727976	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	527610	usd
	us-gaap	Operating Expenses OperatingExpenses	967515	usd
	us-gaap	Operating Expenses OperatingExpenses	932618	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-866364	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-602284	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1172115	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1079912	usd
CY2022Q2	us-gaap	Interest Expense Other InterestExpenseOther	477745	usd
CY2021Q2	us-gaap	Interest Expense Other InterestExpenseOther	448996	usd
	us-gaap	Interest Expense Other InterestExpenseOther	773681	usd
	us-gaap	Interest Expense Other InterestExpenseOther	870377	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	6462	usd
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	136652	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	123894	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	77333	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27593	usd
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	60000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-27593	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-398373	usd
CY2021Q2	GPFT	Gain Loss On Extinguishment Of Debt Related Parties GainLossOnExtinguishmentOfDebtRelatedParties	491998	usd
	GPFT	Gain Loss On Extinguishment Of Debt Related Parties GainLossOnExtinguishmentOfDebtRelatedParties	491998	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-498876	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-744342	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-677380	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1683415	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1365240	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1346626	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1849495	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2763327	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-1365240	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-1346626	usd
	us-gaap	Profit Loss ProfitLoss	-1849495	usd
	us-gaap	Profit Loss ProfitLoss	-2763327	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	559514158	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	518864169	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	561807925	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	521811303	shares
	us-gaap	Net Income Loss NetIncomeLoss	-1849495	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2763327	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44366	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	46113	usd
	GPFT	Amortization Of Debt Discount AmortizationOfDebtDiscount	240446	usd
	GPFT	Amortization Of Debt Discount AmortizationOfDebtDiscount	463217	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	123894	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	77333	usd
	GPFT	Gain Loss On Extinguishment Of Debt Related Parties GainLossOnExtinguishmentOfDebtRelatedParties	491998	usd
	GPFT	Loss On Extinguishment Of Debt LossOnExtinguishmentOfDebt	398373	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	195905	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	239044	usd
	us-gaap	Interest Expense InterestExpense	315335	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	20998	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	32877	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	250054	usd
	GPFT	Loss On Legal Settlement LossOnLegalSettlement	36462	usd
	GPFT	Gain Loss On Inventory Valuation GainLossOnInventoryValuation	68941	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5989	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	188730	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	18970	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	38185	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12057	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	26384	usd
	GPFT	Increase Decrease In Right Of Use Assts IncreaseDecreaseInRightOfUseAssts	-58959	usd
	GPFT	Increase Decrease In Right Of Use Assts IncreaseDecreaseInRightOfUseAssts	-46269	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	76283	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4000	usd
	GPFT	Increase Decrease In Accrued Executive Compensation IncreaseDecreaseInAccruedExecutiveCompensation	300000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	337792	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	145825	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	280964	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-60655	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-45852	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-281394	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-807164	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56679	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56679	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	19871	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	31915	usd
	GPFT	Repayment Of Legal Liability RepaymentOfLegalLiability	12645	usd
	GPFT	Repayment Of Legal Liability RepaymentOfLegalLiability	18000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	450000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	50000	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	3395	usd
	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	3162	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	263245	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	30180	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	250000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	75000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	277334	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	752103	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4060	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-111740	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9095	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	299895	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5035	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	188155	usd
	us-gaap	Interest Paid Net InterestPaidNet	59992	usd
	us-gaap	Interest Paid Net InterestPaidNet	77467	usd
	us-gaap	Stock Issued1 StockIssued1	35127	usd
	us-gaap	Stock Issued1 StockIssued1	1090462	usd
	GPFT	Shares Issued For Conversion Of Notes Payable SharesIssuedForConversionOfNotesPayable	1745818	usd
	GPFT	Shares Issued For Conversion Of Notes Payable SharesIssuedForConversionOfNotesPayable	996620	usd
	GPFT	Shares Issued For Debt Settlement With Related Parties SharesIssuedForDebtSettlementWithRelatedParties	699236	usd
	GPFT	Shares Issued For Compensation SharesIssuedForCompensation	57514	usd
	GPFT	Stock Open Compensation StockOpenCompensation	20998	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4679747	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	250064	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1090460	usd
	GPFT	Shares Issued Upon Warrant Exercise SharesIssuedUponWarrantExercise	250000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	996620	usd
	GPFT	Stock Issued During Period Value Issued For Related Party StockIssuedDuringPeriodValueIssuedForRelatedParty	1191234	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	32877	shares
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	75000	usd
	us-gaap	Profit Loss ProfitLoss	-2763327	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3556819	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5814785	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	57809	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	35127	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1745818	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	20998	shares
	us-gaap	Profit Loss ProfitLoss	-1849495	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5804528	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zCURHJ3XhKp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_823_z6uCtfPBqbZg">ORGANIZATION AND NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Overview</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grapefruit Boulevard Investments, Inc. (“we”, “our”, “us”, “Grapefruit”, “GBI”, or “the Company”) was formed as a California corporation on August 28, 2017 and began operation in September 2017. On July 10, 2019, Grapefruit acquired Imaging3, Inc. (“IGNG”) in a reverse acquisition (the “Acquisition”). Under the terms of a Share Exchange Agreement by and among IGNG, Grapefruit and Grapefruit’s shareholders, IGNG issued to Grapefruit’s existing shareholders approximately <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20190710__srt--TitleOfIndividualAxis__custom--GrapefruitsShareholdersMember__us-gaap--BusinessAcquisitionAxis__custom--Imaging3IncMember__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember_zysZZwe82Vk9" title="Acquisition ownership percentage">81</span>% of the post-Acquisition IGNG common shares and the IGNG shareholders retained <span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20190710__srt--ConsolidatedEntitiesAxis__custom--GrapefruitBoulevardInvestmentsIncMember__srt--TitleOfIndividualAxis__custom--CurrentShareholdersMember__us-gaap--BusinessAcquisitionAxis__custom--PostAcquisitionMember__us-gaap--TypeOfArrangementAxis__custom--ShareExchangeAgreementMember_znEHIOR0qHH7" title="Acquisition ownership percentage">19</span>% of the post-Acquisition IGNG common shares. As a result, our financial statements are prepared using the acquisition method of accounting with Grapefruit as the accounting acquirer and IGNG treated as the legal acquirer and accounting acquiree. On December 16, 2019, Grapefruit filed the necessary paperwork with the Financial Industry Regulatory Authority (“FINRA”) and OTC Markets to effect the Company Name and Ticker symbol changes from “IGNG” to “GPFT” formally changing our corporate name from Imgaing3, Inc. to Grapefruit USA, Inc., a Delaware corporation whose stock is trading under the Ticker Symbol “GPFT”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s annual distribution licensure renews again on June 13, 2023. Our annual manufacturing license was renewed by the California Department of Health. Grapefruit has not yet applied for a license to cultivate cannabis flowers and will not until construction of our cultivation facility has been substantially completed. We own two acres of fully entitled cannabis real property located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park where we intend to build a <span id="xdx_907_eus-gaap--AreaOfLand_iI_pid_uSquareFoot_c20220630_zXFofbCLBZP3" title="Area of land">30,000</span> square foot fully licensed cannabis facility as more fully described below. The location within Coachillin’ allows the Company to apply for and hold every cannabis license available under the California Cannabis laws.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">The “Mothership” Cultivation & Lab Facility</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, Grapefruit obtained a development permit to build a <span id="xdx_90C_eus-gaap--AreaOfLand_iI_pid_uSquareFoot_c20210731_zEQlmjKk6pl3" title="Area of land">30,000</span> square foot “Mothership” facility intended to house a state-of-the-art indoor grow as well as a separately licensed distribution hub and laboratory that will produce the patented Hourglass line of topical creams as well as high quality extracts from trim generated by processing the indoor cannabis flowers. We intend to obtain CGMP certification for the lab pursuant to the Good Manufacturing Practice regulations enforced by the Federal Drug Administration (“FDA”). We expect that our facility will meet proper design, monitoring, and manufacturing control processes to assure the strength, quality, and purity of all Hourglass products we manufacture. We anticipate the FDA to mandate all cannabis facilities to be CGMP certified to continue in operation if cannabis becomes legalized by the federal government.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Summit Boys</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2021, the Company purchased control of Summit Boys, Inc., a cannabis extraction brand with product lines in retail stores throughout the State of California. The Company is continuing the Summit Boys’ business without interruption and is currently selling its branded products in California through Grapefruit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summit Boys’ premium extracts include sugar, crumble, badder, live resin, diamonds, budder, sauce, caviar and other extracted cannabis products, which are currently placed in licensed dispensaries throughout California and are protected by United States of America Trademark Reg. No. 6406802, July 6, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Grapefruit’s Business Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, we shifted our corporate focus from distribution operations to further development of our patented Hourglass™ Time Release THC+CBD-Infused Topical Cream. Hourglass is the first and only patented Full Spectrum THC+ Cannabinoid Topical delivery Cream that provides its users with a full body, synergistic entourage effect that was previously only available by smoking, vaping or eating cannabis products such as cannabis flowers and gummies. Our Topical Cream is scientifically designed to deliver the full effects of THC combined with a broad range of cannabinoids for a user’s overall health, wellness, and well-being. Hourglass products are laboratory tested. Test results published on every package via a designated QR Code. There is no other topical cream product on the market with our patented technology that provides users with the holistic benefits of the entourage effect of THC+CBD, CBN, CBG, Delta8, THCV and CBE. Hourglass™ is currently available in licensed retail and mobile cannabis dispensaries in Central California and Los Angeles County, California, USA. Hourglass™ is not intended for use to cure, mitigate, treat, or prevent disease and we are not making any such claims.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, we decided to bring our patented Hourglass™ Time Release THC+CBD-Infused Topical Cream to the federally legalized Canadian cannabis marketplace. In January 2022, the company’s licensed Canadian distribution partner Medz Cannabis filed a Notice of New Cannabis Product (“NNCP”) with Health Canada on Grapefruit’s behalf for its Hourglass THC+CBD Topical cream. Health Canada is the Canadian federal government department that is responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. Under Canada’s Federal Cannabis Regulatory scheme, Health Canada must be notified of a company’s intent to sell a cannabis product that has not previously been sold in the country.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2022, Health Canada approved the Company’s NNCP application authorizing Grapefruit to sell its patented Hourglass™ Time Release THC+CBD-Infused Topical Cream to licensed retail outlets throughout Canada under NNCP ID No. NP-V2EHUWO907.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, we expanded our distribution efforts to include retail and wholesale sales of our Summit Boys branded products in California.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grapefruit holds its State of California annual licensing from the Bureau of Cannabis Control and the California Department of Public Health. The Company has a permanent annually renewable license as opposed to a provisional or temporary one. The Company is one of the earliest registered distribution companies in the State of California to have an annually renewable license as opposed to the provisional licenses previously granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grapefruit operates within the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park (the “Park”), located in Desert Hot Springs, California, 14 miles north of downtown Palm Springs. The Park is the first and largest cooperative canna-business compound of its kind. It is unique in that the landowners each own a proportionate interest in a collaborative owner’s association, which allows them to share much of the park overhead such as clean cultivation water, park security and access to agricultural power rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Distribution</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In early 2021, the Company temporarily suspended its ‘bulk’ purchase and distribution of wholesale cannabis flower due to negative market forces in the wholesale cannabis market beyond the control of the Company. The Company can and will resume wholesale ‘bulk’ cannabis sales and distribution operations when market forces indicate such resumption is appropriate. Nonetheless, the Company continues to distribute ‘bulk’ concentrates to support our Summit Boys brand in California. In March 2022, we expanded our distribution efforts to include retail and wholesale sales of our Summit Boys branded products in California.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Manufacturing</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company owns a fully licensed ethanol extraction facility in the City of Desert Hot Springs, CA. The Company owns and operates a Type 6 Ethanol Extraction Plant which removes the essential cannabis compounds, such as THC Distillate, that we, and others use, to produce cannabis products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grapefruit manufactures its patented Hourglass™ Time Release THC+CBD-Infused Topical Cream at its Coachillin’ facility which allows us to maintain strict quality control standards. In addition, Grapefruit’s extraction lab produces high quality distillate or “Honey Oil” from cannabis trim sourced by Grapefruit. THC Honey Oil is a fundamental cannabis commodity which serves as the active ingredient in products from infused edibles to tinctures/creams. Grapefruit chose to set up its extraction laboratory in the City of Desert Hot Springs because, among other factors, the city does not tax the manufacture of oil by Grapefruit at its Desert Hot Springs extraction facility, thereby providing Grapefruit with an additional competitive advantage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Binding Letter of Intent to Acquire Diagnostic Lab Corporation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 22, 2022, the Company entered into a Memorandum of Understanding with Diagnostic Lab Corporation, Inc., a Delaware corporation (“DLC”). On June 30, 2022, the Company entered into a Binding Letter of Intent (“LOI”) with DLC. Pursuant to the LOI, the Company will acquire the assets of DLC, its IP and all of its affiliated entities for a combination of cash and a to-be-determined number of the Company’s $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220630__dei--LegalEntityAxis__custom--BindingLetterOfIntentMember_zgdsVxfru7W6" title="Common stock, par value">0.0001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">par value common stock. The Company and DLC will jointly recapitalize the Company by raising $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn5n6_c20220101__20220630__dei--LegalEntityAxis__custom--BindingLetterOfIntentMember_zWVuPRz9V67b" title="Proceeds from issuance initial public offering">12.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million (inclusive of a currently committed $<span id="xdx_906_eus-gaap--NotesPayable_iI_pn5n6_c20220630__dei--LegalEntityAxis__custom--BindingLetterOfIntentMember_z3hHpVZFH1m" title="Notes payable">5.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million debt facility) which will enable the Company to construct its <span style="color: #202124; background-color: white">Good Manufacturing Practices (“cGMP”)</span> certified Desert Hot Springs, CA, Coachillin Park. The “Mothership” facility which will house a state-of-the-art indoor cultivation, manufacturing laboratory and distribution facility. In addition, the recapitalization will fund the Company’s Hourglass 510K Project, the Medical Study of the effects of Hourglass powered products on osteoarthritis sufferers and afford sufficient working capital and interest payment reserves to allow the post-transaction Company to reach positive cash flow. As of August 20, 2022, <span style="background-color: white">the Company is in the process of finalizing its due diligence on DLC and is in the final stages of negotiating the terms of its anticipated financing and structuring of the transaction documents. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Area Of Land AreaOfLand	30000
CY2021Q3	us-gaap	Area Of Land AreaOfLand	30000
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zVp4dMEEKkEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zQ5DQ0rt70xa">Use of Estimates</span></i></b> – The preparation of our financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of our financial statements and the reported amounts of revenues and expenses during the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term. The company’s most significant estimates related to useful life for depreciation, the value of long-lived assets and related impairment, and provision for income taxes of property and equipment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
	us-gaap	Inventory Write Down InventoryWriteDown	68941	usd
	GPFT	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	561807925	shares
CY2021	GPFT	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	515339023	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	3498	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1849495	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5504670	usd
	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_84E_eus-gaap--DerivativesReportingOfDerivativeActivity_zvcxqYKl7oZ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_860_zkTYGyKqzZjc">Derivative Financial Instruments</span> - </i></b>The Company generally does not use derivative financial instruments to hedge exposures to cash-flow risks or market-risks that may affect the fair values of its financial instruments. The Company utilizes various types of financing to fund its business needs, including convertible notes and warrants and other instruments not indexed to our stock. The Company is required to record its derivative instruments at their fair value. Changes in the fair value of derivatives are recognized in earnings in accordance with ASC 815. The Company’s only asset or liability measured at fair value on a recurring basis is its derivative liability associated with warrants to purchase common stock and convertible notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	127392	usd
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	127392	usd
	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	more than 50 percent
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zroF1JGS0L22" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zw87m21pkX4i">Concentration of Credit Risk</span></i></b> – Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	762	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	278422	usd
CY2022Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	250054	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1849495	usd
CY2022Q2	GPFT	Working Capital Deficit WorkingCapitalDeficit	6876837	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18675659	usd
CY2022Q2	GPFT	Operating Lease Right Of Use Asset Current And Non Current OperatingLeaseRightOfUseAssetCurrentAndNonCurrent	15928	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	15928	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	24932	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	6804	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10206	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17010	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1082	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	15928	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	85294	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	84951	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	20000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	234018	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	304331	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	339312	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	389282	usd
CY2022Q2	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	690	usd
CY2021Q4	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	20904	usd
	us-gaap	Inventory Write Down InventoryWriteDown	68941	usd
CY2022Q2	GPFT	Vehicle Vehicle	41142	usd
CY2021Q4	GPFT	Vehicle Vehicle	41142	usd
CY2022Q2	GPFT	Furniture And Equipment FurnitureAndEquipment	7494	usd
CY2021Q4	GPFT	Furniture And Equipment FurnitureAndEquipment	7494	usd
CY2022Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	302636	usd
CY2021Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	302636	usd
CY2022Q2	GPFT	Extraction Laboratory ExtractionLaboratory	126707	usd
CY2021Q4	GPFT	Extraction Laboratory ExtractionLaboratory	126707	usd
CY2022Q2	GPFT	Warehouse Facility WarehouseFacility	50158	usd
CY2021Q4	GPFT	Warehouse Facility WarehouseFacility	50158	usd
CY2022Q2	us-gaap	Land And Land Improvements LandAndLandImprovements	1505012	usd
CY2021Q4	us-gaap	Land And Land Improvements LandAndLandImprovements	1505012	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	307888	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	263522	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1725261	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1769627	usd
	us-gaap	Depreciation Depreciation	44366	usd
	us-gaap	Depreciation Depreciation	46113	usd
CY2018Q2	GPFT	Capital Lease Term CapitalLeaseTerm	P48M
CY2018Q2	GPFT	Capital Lease Monthly Payments CapitalLeaseMonthlyPayments	4575	usd
CY2018Q2	GPFT	Capital Lease Interest Rates CapitalLeaseInterestRates	0.15	pure
CY2018Q2	GPFT	Capital Lease Maturity Date CapitalLeaseMaturityDate	February 2022
CY2019Q2	GPFT	Capital Lease Term CapitalLeaseTerm	P48M
CY2019Q2	GPFT	Capital Lease Monthly Payments CapitalLeaseMonthlyPayments	1935	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	702581	usd
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11710465	shares
CY2022Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	11610	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	7740	usd
CY2022Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	19350	usd
CY2022Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	386	usd
CY2022Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	18964	usd
CY2022Q1	us-gaap	Related Party Costs RelatedPartyCosts	56000	usd
CY2022Q2	us-gaap	Related Party Costs RelatedPartyCosts	56000	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1200000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	545818	usd
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	0.075	pure
CY2022Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	23277573	shares
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	241000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	3966048	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1200000	usd
	GPFT	Debt Conversion Converted Instrument Amount Discount DebtConversionConvertedInstrumentAmountDiscount	90043	usd
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	2676005	usd
CY2022Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1265826	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M2D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	750000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.35
CY2021Q4	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	127392	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-123894	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2527000	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	57809	usd
	GPFT	Shares Issued Related To Settlement Shares Value SharesIssuedRelatedToSettlementSharesValue	35127	usd
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	23277573	shares
	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	6349937	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	250064	usd
	GPFT	Shares Issued Related To Settlement Shares Value SharesIssuedRelatedToSettlementSharesValue	2281695	usd
	GPFT	Shares Issued Upon Warrant Exercise Shares SharesIssuedUponWarrantExerciseShares	2000000	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.125
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	750000	shares
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.025
CY2021Q4	GPFT	Stock Issued During Period Vesting Of Shares StockIssuedDuringPeriodVestingOfShares	250000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	250000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
	GPFT	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y25D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	750000	shares
	GPFT	Share Based Compensation Arrangement By Share Based Payment Award Options Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGranted	0.025
	GPFT	Share Based Compensation Arrangement By Share Based Payment Award Term Options Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOptionsGranted	P4Y9M3D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1000000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y10D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M2D
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	20000000	shares
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.075
CY2022Q2	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs	3498	usd
CY2022Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	8869	usd

Files In Submission

Name	View Source	Status
0001493152-22-023697-index-headers.html	Edgar Link	pending
0001493152-22-023697-index.html	Edgar Link	pending
0001493152-22-023697.txt	Edgar Link	pending
0001493152-22-023697-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
gpft-20220630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
gpft-20220630_def.xml	Edgar Link	unprocessable
gpft-20220630_cal.xml	Edgar Link	unprocessable
gpft-20220630_lab.xml	Edgar Link	unprocessable
gpft-20220630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GPFT
Grapefruit USA, Inc Stock $gpft

2022 Q3 Form 10-Q Financial Statement

#000149315222023697 Filed on August 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GPFT Grapefruit USA, Inc Stock $gpft

2022 Q3 Form 10-Q Financial Statement

#000149315222023697 Filed on August 22, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GPFT
Grapefruit USA, Inc Stock $gpft